Literature DB >> 7511159

Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data.

A Boiardi1, A Silvani, S Valentini, A Salmaggi, A Allegranza, G Broggi.   

Abstract

Non-Hodgkin's lymphoma of the central nervous system (NHL-CNS) is thought to account for about 1% of primary brain tumours. Radiation therapy has mainly been applied to treat cerebral lymphoma, but the low cure rate and the lack of enduring response have stimulated the search for alternatives. With the aim of postponing radiotherapy as long as possible, we tested the efficacy of a M-BACOD schedule administered immediately after histological diagnosis in 14 patients. After two M-BACOD courses 10 (71%) patients displayed an objective response (i.e. were apparently tumour-free when examined by CT). In 6 (60%) M-BACOD-responsive patients, radiotherapy was delayed for 5 months (without recurrences after a follow-up ranging from 9 to 18 months). Moreover, in 3 M-BACOD-responsive patients, no recurrence took place (even without radiotherapy) after a follow-up of 6-12 months. We conclude that radiation can be postponed after chemotherapy or delayed until tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7511159     DOI: 10.1007/bf00869771

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

1.  Adjuvant chemotherapy for primary lymphoma of the central nervous system.

Authors:  M C Chamberlain; V A Levin
Journal:  Arch Neurol       Date:  1990-10

2.  Primary malignant lymphomas of the central nervous system.

Authors:  J M Henry; R R Heffner; S H Dillard; K M Earle; R L Davis
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  Radiation therapy in the management of primary malignant lymphoma of the brain.

Authors:  M P Berry; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-01       Impact factor: 7.038

4.  Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathological study.

Authors:  Y T So; J H Beckstead; R L Davis
Journal:  Ann Neurol       Date:  1986-11       Impact factor: 10.422

5.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

6.  Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford.

Authors:  T L Helle; R H Britt; T V Colby
Journal:  J Neurosurg       Date:  1984-01       Impact factor: 5.115

7.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).

Authors:  A T Skarin; G P Canellos; D S Rosenthal; D C Case; J M MacIntyre; G S Pinkus; W C Moloney; E Frei
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

Review 8.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

9.  Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM).

Authors:  A Boiardi; A Silvani; D Croci; E Perego; C L Solero
Journal:  Ital J Neurol Sci       Date:  1992-10

10.  Primary lymphoma of the central nervous system.

Authors:  L Letendre; P M Banks; D F Reese; R H Miller; P W Scanlon; J M Kiely
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

View more
  2 in total

1.  Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature.

Authors:  B Pirotte; M Levivier; S Goldman; J M Brucher; J Brotchi; J Hildebrand
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

2.  Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.

Authors:  M D de Smet; V S Vancs; D Kohler; D Solomon; C C Chan
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.